[
    [
        {
            "time": "2023-10-01",
            "original_text": "Eli Lilly CEO: 'It's time for a change in the drug pricing system",
            "features": {
                "keywords": [
                    "Eli Lilly",
                    "CEO",
                    "change",
                    "drug pricing"
                ],
                "sentiment_score": 0.6,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Eli Lilly CEO: 'It's time for a change in the drug pricing system'",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-10-01",
            "original_text": "Should You Be Tempted To Sell Eli Lilly and Company (NYSE:LLY) Because Of Its PE Ratio?",
            "features": {
                "keywords": [
                    "Eli Lilly",
                    "PE Ratio",
                    "sell"
                ],
                "sentiment_score": -0.4,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Should You Be Tempted To Sell Eli Lilly and Company (NYSE:LLY) Because Of Its PE Ratio?",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-10-01",
            "original_text": "Eli Lilly CEO: 'It's time for a change in the drug prici...}",
            "features": {
                "keywords": [
                    "Eli Lilly",
                    "CEO",
                    "change",
                    "drug pricing"
                ],
                "sentiment_score": 0.6,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Eli Lilly CEO: 'It's time for a change in the drug prici...}",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-10-01",
            "original_text": "Allergan (AGN) Presents Positive Data on Glaucoma Candidate",
            "features": {
                "keywords": [
                    "Allergan",
                    "positive data",
                    "Glaucoma",
                    "candidate"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Allergan (AGN) Presents Positive Data on Glaucoma Candidate",
                "Correlation": 8,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-10-01",
            "original_text": "Merck's Keytruda Gets FDA Nod for 2nd Lymphoma Indication",
            "features": {
                "keywords": [
                    "Merck",
                    "Keytruda",
                    "FDA",
                    "Lymphoma"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Merck's Keytruda Gets FDA Nod for 2nd Lymphoma Indication",
                "Correlation": 9,
                "Sentiment": 10,
                "Importance": 10,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 7,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 10
            }
        },
        {
            "time": "2023-10-01",
            "original_text": "This Day That Year: Athenex",
            "features": {
                "keywords": [
                    "Athenex"
                ],
                "sentiment_score": 0.0,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "This Day That Year: Athenex",
                "Correlation": 3,
                "Sentiment": 5,
                "Importance": 2,
                "Impact": 2,
                "Duration": 2,
                "Entity_Density": 4,
                "Market_Scope": 3,
                "Time_Proximity": 3,
                "Headline_Structure": 4,
                "Source_Recency": 2
            }
        }
    ]
]